CARbon monoxidE intoxiCatiOn in Korea: Prospective Cohort (CARE CO Cohort)
Launched by WONJU SEVERANCE CHRISTIAN HOSPITAL · Jul 23, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The CARE CO Cohort study is looking at how different treatments help people who have experienced carbon monoxide (CO) poisoning. This study is important because CO poisoning can lead to serious problems with the brain and heart, and the researchers want to understand both the immediate and long-term effects of this condition. They will be monitoring patients closely to see how well the treatments work and what complications might arise.
To participate in this study, individuals must have had a recent case of CO poisoning. Everyone, regardless of age or gender, is welcome to join as long as they agree to be part of the study. Participants can expect regular check-ups with doctors who will keep an eye on their recovery and any potential complications. This trial aims to improve our understanding of CO poisoning and ultimately enhance treatment strategies for those affected.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Acute CO poisoning
- Exclusion Criteria:
- • Declined to enrollment in the study
About Wonju Severance Christian Hospital
Wonju Severance Christian Hospital is a leading healthcare institution based in South Korea, renowned for its commitment to innovative medical research and high-quality patient care. As a prominent clinical trial sponsor, the hospital is dedicated to advancing medical knowledge through rigorous scientific studies and trials across various therapeutic areas. With a multidisciplinary team of experienced researchers and healthcare professionals, Wonju Severance Christian Hospital strives to improve treatment outcomes and enhance the overall health and well-being of patients. Its state-of-the-art facilities and adherence to ethical standards ensure a robust framework for conducting clinical research that meets both local and international regulatory requirements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wonju, Gangwon, Korea, Republic Of
Patients applied
Trial Officials
Yong Sung Cha, MD
Principal Investigator
Wonju Severance Christian Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials